AWCI
VTGN icon

Alpine Woods Capital Investors’s VistaGen Therapeutics VTGN Stock Holding History

Alpine Woods Capital Investors’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,500
Closed -$50K – 440
2017
Q4 		$50K Buy
+1,500
New +$49.5K ﹤0.01% 441

Other funds holding VTGN

SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
CA
Corrado Advisors Ramsey, New Jersey $192M AUM 20.53% 1-Year Est. Return
DADC
D.A. Davidson & Co Great Falls, Montana $16.5B AUM 19.94% 1-Year Est. Return
Parallax Volatility Advisers
Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Alpine Woods Capital Investors's VTGN Position: Q1 2018 in Review

Alpine Woods Capital Investors sold out of VistaGen Therapeutics (VTGN) in Q1 2018, closing a stake of 1,500 shares — an estimated $50K sold.

Alpine Woods Capital Investors first reported a position in VTGN in Q4 2017 and held it in 1 quarter. The position peaked at $50K in Q4 2017. 20 funds tracked by Wall St. Rank hold VTGN as of Q1 2018.

  • Alpine Woods Capital Investors reported no remaining VistaGen Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Alpine Woods Capital Investors sold 1,500 VistaGen Therapeutics shares in Q1 2018, an estimated $50K.
  • Alpine Woods Capital Investors first reported a position in VistaGen Therapeutics in Q4 2017 and held it in 1 quarter.
  • Alpine Woods Capital Investors's VistaGen Therapeutics position peaked at $50K in Q4 2017.
  • 20 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2018.

Based on Alpine Woods Capital Investors's 13F filing for Q1 2018, filed 9 May 2018.